Translate Bio Inc

NASDAQ : TBIO

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. As of September 13, 2021, Translate Bio, Inc. operates as a subsidiary of Sanofi.

Information

Website
http://www.translate.bio
Sector
Healthcare
Industry
Biotechnology
Type
Common Stock
Country
United States

Price

USD 2.80

Symbol

TBIO

Type

Common Stock

Previous Close

 :

2.80

52 Week Range

 :

1.08 - 4.72

Volume

 :

34,444.00

Average Volume

 :

46,414.00

High

 :

2.96

Low

 :

2.78

Change

 :

0.00

Percent change (%)

 :

0.00

Stakeville

A Free-to-Play Trading Game. Sharpen your skills, trade stocks, and have fun!

Play Now
Getting Started
Get Your Free Account For Educational Purpose Knowledgebase
Legal
Cookie Policy Privacy Policy Terms & Conditions
Customer Service
Help Desk Support Stakeville Newsletter
Stay Connected
Contact Us Official Blog About Us
Disclaimer: Stakeville is a simulation trading game. All trades and stock prices are fictional and do not reflect real-world markets. This game is for entertainment purposes only and does not involve real financial transactions. Read more...